Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy

BACKGROUND: Patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) receiving platinum-based chemotherapy as their first-line treatment have a dismal prognosis, with a median overall survival (OS) of ~7 months. Methotrexate is sometimes used following platinum f...

Descripción completa

Detalles Bibliográficos
Autores principales: Machiels, Jean-Pascal H, Licitra, Lisa F, Haddad, Robert I, Tahara, Makoto, Cohen, Ezra EW
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4079914/
https://www.ncbi.nlm.nih.gov/pubmed/24973959
http://dx.doi.org/10.1186/1471-2407-14-473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4079914/
https://www.ncbi.nlm.nih.gov/pubmed/24973959
http://dx.doi.org/10.1186/1471-2407-14-473

Ejemplares similares